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Chronotype Genetic Variant in 
PER2 is Associated with Intrinsic 
Circadian period in Humans
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Daniel Aeschbach2,3,7, Clare Anderson2,3,11, Andrew C. Bjonnes4,6, Sean W. Cain  2,3,11,  
Daniel A. Cohen2,3, Timothy M. Frayling8, Joshua J. Gooley2,3,12, Samuel E. Jones  8,  
Elizabeth B. Klerman2,3, Steven W. Lockley2,3, Mirjam Munch2,3,13, Shantha M. W. Rajaratnam2,3,11, 
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the PERIOD2 (PER2) gene is a core molecular component of the circadian clock and plays an important 
role in the generation and maintenance of daily rhythms. Rs35333999, a missense variant of PER2 
common in European populations, has been shown to associate with later chronotype. Chronotype 
relates to the timing of biological and behavioral activities, including when we sleep, eat, and exercise, 
and later chronotype is associated with longer intrinsic circadian period (cycle length), a fundamental 
property of the circadian system. Thus, we tested whether this PER2 variant was associated with 
circadian period and found significant associations with longer intrinsic circadian period as measured 
under forced desynchrony protocols, the ‘gold standard’ for intrinsic circadian period assessment. Minor 
allele (T) carriers exhibited significantly longer circadian periods when determinations were based on 
either core body temperature or plasma melatonin measurements, as compared to non-carriers (by 
12 and 11 min, respectively; accounting for ~7% of inter-individual variance). These findings provide a 
possible underlying biological mechanism for inter-individual differences in chronotype, and support 
the central role of PER2 in the human circadian timing system.
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The Period gene was the first circadian gene discovered by Konopka and Benzer in Drosophila1 and the central 
gene on which the concept of a transcriptional-translational feedback loop was based2. Mammalian homologues, 
including PER2, were found to be expressed in the suprachiasmatic nucleus (SCN)3, and have been shown to 
influence circadian period4,5. The other two mammalian homologues, PER1 and PER3, have been reported to 
associate with measures indirectly related to circadian period, i.e., circadian phenotypes and chronotype6–11. 
Together, these studies highlight the central role of the Period genes and specifically PER2 in the generation and 
maintenance of circadian rhythmicity and timing. However, to date, none of the PERs have been shown to be 
related to circadian period measured under the ‘gold standard’ forced desynchrony conditions in humans, neces-
sary and designed to uncover the endogenous circadian period independent of the dark/light, sleep/wake, fasting/
feeding, and other behavioral influences.
A PER2 variant, rs35333999 (p.Val903Ile), which is common in people of European ancestry but rare in 
African and East Asian populations (https://www.ncbi.nlm.nih.gov/snp/rs35333999#frequency_tab), was 
recently associated with chronotype in a large genome-wide association study (GWAS)12 showing a more 
evening-type preference in carriers of the minor allele (T) than in those with the non-T allele (C/C) genotype. 
Chronotype is genetically influenced, but previous studies using a candidate-gene approach exhibited limited 
replicability7,8,13–22. More recently, GWAS have identified associations of single nucleotide polymorphisms with 
chronotype using an unbiased approach, as opposed to candidate gene testing, in large cohorts (https://www.
ncbi.nlm.nih.gov/pubmed/30696823)12,23. These studies have identified several genetic associations in genomic 
regions harboring circadian genes, including genes PER2, PER3, Vasoactive intestinal peptide (VIP), and F-Box 
and Leucine Rich Repeat Protein 3 (FBXL3), which is consistent with the hypothesis that common variation 
influencing circadian genes impacts on phenotypic chronotype. Defining the causal variant and causal gene will 
require additional work, however. Importantly, PER2 rs35333999 represents the strongest association signal that 
peaks within a circadian gene12. This PER2 variant encodes a missense single nucleotide polymorphism (SNP) in 
exon 19 in the canonical transcript, is conserved across mammalian species, and is predicted to be deleterious to 
the PER2 protein (probably damaging, score 0.963)24. Furthermore, the SNP lies in the 3′UTR of a non-canonical 
PER2 transcript and may also have a regulatory role, as it is predicted to alter several transcription factor binding 
sites25. It is unknown, however, whether this missense variant is causal or simply a marker in linkage disequi-
librium with a known or unknown causal variant. Notably, this variant is in strong linkage disequilibrium with 
regulatory variants rs77939198 (pair-wise r2 = 0.83, D’ = 0.94) and rs960783 (pair-wise r2 = 0.64, D’ = 0.94), both 
of which are annotated with chromatin marks and protein binding sites from the Roadmap Epigenomics and 
Encyclopedia of DNA Elements (ENCODE) projects25. We therefore hypothesized that this polymorphism would 
affect intrinsic circadian period, in addition to correlated phenotypes chronotype, sleep timing, circadian phase, 
and circadian phase angle according to genotype in this study.
Results
We tested the association of PER2 rs35333999 (p.Val903Ile) with self-reported chronotype (morningness- 
eveningness preference) in the full UK Biobank dataset of unrelated individuals of European ancestry (n up to 
335,789), extending the sample size of our previous genome-wide association analysis based on an interim release 
of this dataset12 by up to 235,369 additional individuals. We observed genome-wide significant association of 
rs35333999 with morningness-eveningness preference; with the rare rs35333999 T allele conferring increased 
eveningness in analysis of categorical chronotype (p = 10−14) and dichotomized extremes (p = 10−9; Table 1, 
Supplemental Fig. 1). This larger analysis confirms the SNP association seen in the previous study12, as the statis-
tical evidence for categorical chronotype strengthened from p = 10−8 in the nested smaller sample (n = 100,420) 
to p = 10−14 in the current sample (n = 335,789), with similar effect estimates. Conditional association analysis 
adjusting for the primary association signal in this genomic region (represented by SNP rs80271258) confirmed 
that the association of PER2 rs35333999 with chronotype is independent of the primary signal and itself robust 
(Table 1, Supplemental Fig. 2).
To discern underlying mechanisms, we tested the association of PER2 rs35333999 with circadian phenotypic 
measures in 196 healthy men and women of European ancestry who participated in highly controlled inpa-
tient physiological protocols. Demographics, circadian measures and results of association testing from these 
participants are presented in Table 2 and Fig. 1 and results from the entire multiethnic sample (up to n = 252) 
SNP E/A
Categorical Chronotype 
(n = 335,789) Beta (SE) p
Extreme Chronotype* 
(n = 26,056 cases, 80,065 
controls) OR (95% CI) p
rs35333999 T/C 0.058 (0.008) 9.7 × 10−14 1.16 (1.10–1.22) 1.5 × 10−9
rs35333999 conditioned on rs80271258 T/C 0.063 (0.008) 6.0 × 10−16 1.18 (1.12–1.23) 4.6 × 10−11
rs80271258 T/C 0.055 (0.006) 3.5 × 10−23 1.14 (1.10–1.18) 5.1 × 10−13
rs80271258 conditioned on rs35333999 T/C 0.058 (0.006) 2.7 × 10−25 1.15 (1.11–1.19) 2.0 × 10−14
Table 1. Results from association testing of PER2 rs35333999 and regional lead SNP rs80271258 with 
chronotype in unrelated UK Biobank participants of white British ancestry. E/A = effect/alternative allele. Beta 
and standard error (SE) derive from a genetic regression model showing per allelic effect of rs35333999 and 
rs80271258 on chronotype. SNPs rs80271258 and rs35333999 are uncorrelated in European populations 
(r2 < 0.01). Significant results (p < 5 × 10−8) are shown in bold. Results from association testing of rs35333999 
and rs80271258 conditioned on the other SNP demonstrate independence of both association signals. *Evening 
types coded as cases and morning types as controls.
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are presented in Fig. 2, Supplemental Table 1 and Supplemental Fig. 3. Circadian phenotypes included chrono-
type (n = 193), determined by morningness-eveningness questionnaire (MEQ)26; intrinsic period of endogenous 
circadian rhythms of core body temperature (CBT; n = 63) and plasma melatonin (n = 57); circadian phase of 
endogenous CBT (n = 90) and melatonin (n = 102) rhythms; measures of sleep timing while on a self-selected, 
fixed, 8-hour sleep schedule one week prior to inpatient studies (n = 152); and phase angle between endogenous 
circadian phase markers and sleep timing for CBT (n = 88) and melatonin (n = 100).
Circadian period. The PER2 polymorphism was associated with intrinsic circadian period of the endoge-
nous rhythms of core body temperature and circulating melatonin concentrations after adjustment for age, sex 
and population structure using 5 principal components of ancestry (Table 2 and Fig. 1). T-allele carriers exhib-
ited a significantly longer intrinsic circadian period than non-T carriers for CBT (mean ± SE; 24.34 ± 0.17 h vs. 
24.14 ± 0.20 h; p = 0.030) and melatonin (24.34 ± 0.18 h vs. 24.15 ± 0.19 h; p = 0.039). This represents a mean dif-
ference of 0.20 hours (12 minutes) for CBT period and a mean difference of 0.19 hours (11 minutes) for melatonin 
period between genotype groups and represents 7.1% of population variance in temperature period and 6.9% of 
variance in melatonin period in participants of European ancestry from our sample. Results were similar in the 
full multiethnic sample (see Fig. 2 and Supplemental Table 1). Sensitivity analysis using the unequal variances 
t-test to account for unequal sample size (Welch’s t-test for rs35333999 T carriers vs CC) shows a consistent direc-
tion of effect in those of European ancestry (melatonin period p = 0.189; CBT period p = 0.097) and reached sig-
nificance for temperature period in the multiethnic sample (melatonin period p = 0.053; CBT period p = 0.032).
Chronotype. Analysis of rs35333999 with composite MEQ score showed no significant association in the 
European-only group (p = 0.210; Table 2) or in the full multiethnic sample (p = 0.120; Supplemental Table 1 
and Supplemental Fig. 3). Given the magnitude of the effect observed in the large UK Biobank GWAS study 
(n = 100,420)12, statistical power to detect the association with chronotype in the current analysis was only 6.2% 
in participants of European ancestry, and only 6.7% in the multi-ethnic sample.
Discussion
The T-allele of PER2 rs35333999 was associated with self-reported evening chronotype in a population-scale sam-
ple and with longer intrinsic circadian period as assessed in highly controlled in-laboratory circadian protocols. 
The consistent direction and magnitude of effect on intrinsic circadian period based on two endogenous circadian 
phase markers, CBT and circulating plasma melatonin rhythms, suggests a difference in the intrinsic period of the 
master circadian pacemaker located in the hypothalamic suprachiasmatic nucleus (SCN). The significant associa-
tion between the minor allele of rs35333999 and longer period of body temperature and plasma melatonin is also 
consistent with published reports showing an association of evening chronotype with longer circadian period27,28.
This is the first report of a genetic association with intrinsic circadian period directly measured in humans 
using forced desynchrony protocols, specifically designed to precisely determine this physiological measure (see 
Methods section)29,30. A previous study reported genetic linkage between another PER2 marker (D2S395) and 
Advanced Sleep Phase Disorder in a multi-generational family31. This very rare mutation (minor allele frequency 
Phenotype n Mean (SD) n Mean T Carriers n
Mean Non-T 
Carriers Beta (SE) p
Age (years) 196 26.93 (11.16) 13 26.15 (5.11) 183 26.99 (11.48) — —
Sex (M/F) 196 126/70 13 8/5 183 118/65 — —
MEQ score* 193 52.29 (12.14) 12 47.17 (15.27) 181 52.63 (11.88) −3.87 (3.08) 0.210
CBT period (h) 63 24.16 (0.20) 6 24.34 (0.17) 57 24.14 (0.20) 0.20 (0.09) 0.030
MEL period (h) 57 24.17 (0.19) 5 24.34 (0.18) 52 24.15 (0.19) 0.19 (0.09) 0.039
CBT phase (clock h) 90 5:00 (2:07) 6 4:53 (1:58) 84 5:01 (2:08) 0.19 (0.91) 0.836
MEL phase (clock h) 102 22:25 (1:52) 5 22:49 (1:32) 97 22:24 (1:53) 0.67 (0.82) 0.415
CBT phase angle (h) 88 −3.19 (1.33) 6 −2.88 (1.08) 82 −3.22 (1.35) 0.55 (0.60) 0.360
MEL phase angle (h) 100 −9.49 (1.21) 5 −9.06 (1.10) 95 −9.51 (1.21) 0.57 (0.57) 0.304
Bedtime (clock h) 152 23:57 (1:27) 9 0:17 (1:44) 143 23:56 (1:26) 0.47 (0.47) 0.315
Wake time (clock h) 152 7:59 (1:27) 9 8:17 (1:41) 143 7:58 (1:26) 0.42 (0.47) 0.380
TIB duration (h) 152 8.04 (0.13) 9 7.99 (0.16) 143 8.05 (0.13) −0.06 (0.05) 0.222
TIB midpoint (clock h) 152 3:58 (1:27) 9 4:17 (1:43) 143 3:57 (1:26) 0.44 (0.47) 0.346
Table 2. Phenotype measures by PER2 rs35333999 genotype and results from association testing for in-
laboratory participants of European ancestry. Phenotype means (standard deviation; SD) and the number of 
males/females are listed by rs35333999 genotype: T-allele carriers and non-T carriers. Beta and standard error 
(SE) derive from a genetic regression model showing per allelic effect of rs35333999 on circadian phenotypes, 
adjusted for age, sex and PCs. Significant results (p < 0.05) are shown in bold. Circadian phenotypes include 
MEQ; circadian period, circadian phase and phase angle of CBT and melatonin (MEL). Sleep timing measures 
include bedtime, wake time, time-in-bed duration (TIB), and midpoint of TIB. Sleep phenotypes included 
in this analysis were assessed using call-in data during a fixed 8-hour schedule maintained the week prior to 
admission. *A higher MEQ score reflects more morningness26.
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<0.1%) that causes a serine to glycine change leading to hypophosphorylation of PER2 protein, was found to be 
associated with an early circadian timing of sleep, extreme morning chronotype, and a shorter observed period of 
the sleep-wake and temperature cycles in one individual, though intrinsic period free of influence of self-selected 
light exposure was not assessed in that study (https://www.ncbi.nlm.nih.gov/pubmed/10470086). In the current 
study, a relatively common variant of PER2 (5% allele frequency in the 1000 Genomes European population and 
3.6% in our population of European ancestry) was associated with intrinsic circadian period assessed under con-
ditions free from the influence of self-selected light exposure. This was achieved by studying participants under 
dim light conditions (<15 lux), and by distributing that light exposure across all circadian phases outside the 
range of entrainment of the human circadian pacemaker. This was done in order to minimize the effects of light 
on circadian period. These conditions are critical for accurate assessment of intrinsic circadian period, as retinal 
light exposure has a powerful resetting effect on the human circadian pacemaker that would otherwise confound 
assessment of intrinsic circadian period32. Furthermore, because there are aftereffects of prior light exposure on 
circadian period33, we tried to limit differences in prior history by excluding recent shiftwork and transatlantic 
flights, and had participants maintain a fixed 8-h time in bed for the weeks prior to admission to the laboratory, 
thereby standardizing the prior light history.
The main strength of our study is the precise assessment of endogenous circadian measures in carefully 
designed circadian protocols conducted under rigorously controlled laboratory conditions that are considered 
“gold standard” procedures for determination of circadian period and phase in humans. While chronotype is 
a measure that is relatively easily obtainable using a questionnaire, and therefore scalable and reflects people’s 
preferences, it provides less insight into the relative contribution of environmental/behavioral factors (including 
school, work, and other social demands, exposure to light, caffeine, buildup and discharge of sleep pressure, and 
social demands) versus biology. Furthermore, chronotype cannot distinguish among different biological causes, 
such as differences in endogenous circadian period, circadian rhythm robustness, circadian light sensitivity, and 
homeostatic sleep regulation time constants. For example, the recent finding that PER2 is associated with reduced 
sensitivity of the circadian pacemaker to light in humans34, highlights the relative benefits of biological measures 
of circadian rhythmicity in studying the potential mechanisms underlying chronotype differences. Circadian 
period provides a plausible biological mechanism of the link between the PER2 variant and chronotype, and also 
provides testable hypotheses for future molecular mechanism studies in animal and in vitro models. Intrinsic 
circadian period is a key factor determining behavioral timing. A longer circadian period, leading to a delay of 
the circadian timing system–including the circadian drive for wake and sleep–is a plausible pathway to a later 
Figure 1. Circadian period of core body temperature and melatonin rhythms by PER2 rs35333999 genotype 
in in-laboratory study participants of European ancestry. Data for mean (squares) and individual (circles) 
circadian period of core body temperature (A) and melatonin (B) are shown for T-allele carriers (open symbols) 
and for non-T allele carriers (filled symbols). Vertical lines denote the standard error (SE) measures of the 
mean. T-allele carriers had significantly longer temperature and melatonin circadian periods than non-carriers 
(p = 0.030 and 0.039, respectively).
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chronotype. Thus, to assess the most proximal biological mechanism, we focused specifically on intrinsic circa-
dian period. The second reason to focus on intrinsic circadian period as a potential mechanism underlying the 
link between the PER2 variant and chronotype is that in rodent mutant models, PER2 has been shown to play 
a key role in determining circadian period of the rest activity cycle4,5,31. A third reason to focus primarily on 
circadian period, as opposed to the downstream measures of circadian phase (i.e., timing of circadian markers 
such as core body temperature and melatonin), sleep timing, circadian phase angle (i.e., relative timing of cir-
cadian markers and sleep timing), and chronotype, is that intrinsic circadian period as assessed under forced 
desynchrony protocols can be determined with great precision29, enhancing the statistical power for this outcome 
measure. This may be why those other circadian measures did not show significant differences, though they 
trended consistently later in the T-allele carriers than in the non-carriers, consistent with a longer period27,35.
While significant associations between rs35333999 and circadian period were identified because of a large 
effect (Cohen’s d was 1.08 for CBT period and 1.03 for melatonin period), we likely did not see significant associa-
tions of the SNP with circadian phase due to the overall smaller effect (Cohen’s d was 0.07 for CBT phase and 0.22 
for melatonin phase). One possible explanation is that circadian period is a more proximal phenotype, i.e., one 
that is influenced directly by the PER2 SNP, while phase angle is a measure that is influenced by circadian period, 
but also by exposure to photic and non-photic Zeitgebers (time cues), as well as the accumulation and dissipation 
of homeostatic sleep pressure36. Another potential explanation involves the assessment of sleep timing during 
the week prior to the inpatient protocols in participants who maintained a self-selected, 8-hour sleep duration 
schedule (see Methods section). Therefore, we were unable to assess the influence of rs35333999 on unrestricted 
sleep timing measures or other circadian phenotypes that incorporate them (i.e., phase angle), and may explain 
why there was no significant association with these phenotypes. Further work assessing this SNP in larger datasets 
would be necessary to test this. We also did not replicate the association of PER2 rs35333999 with chronotype in 
the current study. The lack of a significant effect on chronotype was likely due to insufficient power in this sample 
(n = 246) relative to the UK Biobank nested sample (n = 100,420)12 or the larger sample (n = 335,789) in the cur-
rent analysis. Another explanation could be that, similar to phase, chronotype is a less proximal phenotype than 
circadian period and influenced by other factors. While here we show an association of the PER2 SNP rs35333999 
with human endogenous circadian period, future studies are needed to test whether this SNP is the causal variant. 
Such verification will require further experimental studies (e.g., ex vivo cell culture recordings37, or phenotype 
rescue in animal models)38. Furthermore, further studies are needed to test whether this SNP may also relate to 
homeostatic sleep regulation, which has also associates with chronotype36.
Figure 2. Circadian period of CBT and melatonin rhythms by PER2 rs35333999 genotype in the multiethnic 
in-laboratory study sample. Data for mean (squares) and individual (circles) circadian period of core body 
temperature (A) and melatonin (B) are shown for T-allele carriers (open symbols) and for non-T allele carriers 
(filled symbols). Vertical lines denote the standard error (SE) measures of the mean. T-allele carriers had 
significantly longer circadian period of temperature (p = 0.022) and a trend for longer circadian period of 
melatonin (p = 0.051) than non-carriers.
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Although rs35333999 is associated with self-reported chronotype12 and intrinsic circadian period as shown 
here, it is not known if this is the causal variant, or what effect, if any, the allele may have on cell-autonomous cir-
cadian rhythms. This missense SNP is predicted to have deleterious effects on PER2 protein and is also predicted 
to play a role in the circadian molecular mechanism by potentially altering transcription factor binding sites24. 
Future studies are needed to determine the molecular and cellular mechanism by which rs35333999 affects cir-
cadian period. Different research approaches for testing the effect of genetic variants have different strengths and 
limitations. The use of self-reported data collected in humans under ‘free living conditions’, as is the case for the 
association of the SNP with self-reported chronotype in the UK Biobank, have the benefit that these assessments 
can be conducted in large scale studies and have the largest generalizability to the human condition. Such popula-
tions can be useful for discovery of genetic variants influencing behavioral preferences. The downside is that they 
cannot assess physiological mechanisms. The benefit of the association of a SNP with an accurately and precisely 
assessed physiological phenotype, as is the case for endogenous circadian period under the forced desynchrony 
protocol, is that the physiological mechanism can be tested. The molecular mechanism, however, cannot be deter-
mined in these studies and requires genetic manipulation studies in vivo, or in vitro. The systemic integration of 
the effect of the SNP on the physiology can only be assessed in an in vivo system, while the physiological circadian 
mechanism in humans can only accurately be tested in human circadian protocols. The combination of these 
approaches will give a complete picture of the molecular and physiological mechanisms as well as the relevance in 
humans. Thus, ultimately, in vitro experiments are needed to test the influence of rs35333999 on molecular mech-
anisms, including potential alteration of the role of the PER2 protein in the repressor complex of the circadian 
clock and its translocation to the nucleus39.
Limitations. Genetic analyses of the in-laboratory population included a small sample size of rs35333999 
minor-allele (T) carriers for several circadian measures. This was due to the relatively low frequency of this vari-
ant, and the intensive nature of the studies required to obtain accurate and precise assessments of human intrinsic 
circadian period. Despite the limited sample size, we found significant differences of large magnitude in intrin-
sic circadian period, both when using core body temperature and plasma melatonin assessments during forced 
desynchrony protocols. Future studies in larger populations, including other genetic ancestries, are needed to 
verify and expand this finding. As previously noted, we did not find an association between rs35333999 and 
chronotype, as assessed by composite MEQ score, in the in-laboratory sample. The MEQ has been widely used as 
a validated measure of diurnal preference and it has been shown that the MEQ, the reduced MEQ (rMEQ) and 
the Composite Scale of Morningness (CSM) have high correlative validity40; however, these and other scales do 
not necessarily measure the same thing, especially in a cross-cultural context. For example, in a sample of Korean 
adults, the global CSM score as well as two of three subscales (“morningness” and “activity planning”) were 
associated with a non-synonymous PER2 SNP rs93494520. Interestingly, this same PER2 SNP was tested for asso-
ciation with chronotype using the CSM in a sample of Columbian adults and found that two subscales (“activity 
planning” and “morning alertness”) were associated but not total CSM score or the “morningness” subscale22. 
While the current work does not replicate or directly overlap those findings (i.e., a different, uncorrelated PER2 
SNP tested and different measure of chronotype), our findings and previous reports, taken together, suggest that 
circadian regulation of behavior and diurnal preference involves PER2, and as we now show, may involve circa-
dian period.
Conclusion
This is the first study to demonstrate a human genetic variant that associates with intrinsic circadian period. 
Our results show that the PER2 rs35333999 T allele is associated with a longer intrinsic circadian period, which 
provides a likely underlying mechanism for the evening chronotype that was previously associated with this 
SNP. Remarkably, the single SNP explained 7% of the inter-individual differences in intrinsic circadian period 
(11-12 min). To put this into perspective, this difference in intrinsic circadian period conveyed by this single SNP 
is twice as large as the average difference in intrinsic circadian period found between men and women, which 
has been proposed to underlie sex differences in bedtimes, wake times, and sleep disturbances41. Differences in 
intrinsic circadian period and chronotype may also influence the susceptibility for diabetes and other metabolic 
disorders (https://www.ncbi.nlm.nih.gov/pubmed/30705391)42,43. Future studies will be necessary to reveal the 
molecular mechanism by which the genetic variant influences circadian period and chronotype and to determine 
its effect on other chronotype-associated physiologic or disease phenotypes.
Materials and Methods
UK Biobank sample. Study participants were from the UK Biobank prospective study (n = 503,325 adults 
aged 40–69 years), described in detail elsewhere44. For the current analysis, individuals of self-reported non-white 
ethnicity and relatives were excluded to avoid confounding effects. Phenotype and genotype data from 335,789 
unrelated individuals of self-reported British white ancestry who gave informed consent for genetics were used 
in the current analysis. The UK Biobank study was approved by the National Health Service National Research 
Ethics Service (ref 11/NW/0382), all participants provided written informed consent to participate in the UK 
Biobank study, and procedures were conducted in accordance with the relevant guidelines and requirements.
In-lab patient sample. The population sample consisted of 252 healthy men and women who had previ-
ously participated in inpatient physiological research protocols at the Brigham and Women’s Hospital between 
2001 and 2011. Pre-study screening criteria for inclusion consisted of general good health, no medical or psy-
chological/psychiatric conditions and no medications other than certain oral contraceptives; no shiftwork in 
the prior 3 years; and no travel across more than 1 time zone in the prior 3 months. Written informed consent 
was obtained from participants prior to enrollment in this genetic study and they were compensated for their 
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participation. All study procedures received approval by the Partners Health Care Human Research Committee 
and were conducted in accordance to the Declaration of Helsinki.
Phenotypes. Chronotype. In the UK Biobank sample, chronotype was self-reported by a touch-screen 
questionnaire at the baseline visit12. Chronotype was examined both as a categorical trait (n = 335,789) and a 
dichotomous trait, with definite morning responders set to control (n = 80,065) and definite evening responders 
set to case (n = 26,056).
In the in-laboratory sample, chronotype was assessed by MEQ26 from study participants prior to their admis-
sion to the laboratory. This 19-question survey was scored using published criteria and summed to obtain a com-
posite score. MEQ composite score was used as a continuous variable in this analysis.
Sleep timing. For a subset of the inpatient laboratory studies, participants were required to maintain a sta-
ble, self-selected, 8-hour time-in-bed (TIB) schedule for 1–3 weeks prior to admission to the inpatient pro-
tocol. Adherence to this schedule was verified by several means including: wrist actigraphy, sleep diaries, and 
time-stamped daily call-ins at bedtimes and wake times. Bedtime, wake time, TIB duration, and midpoint of 
TIB, were determined from the average call-in times during the week (7 days) immediately prior to admission. 
Participants who did not maintain an 8-hour schedule were not included in the analysis of sleep timing.
In-laboratory circadian phenotypes. Some of the inpatient laboratory protocols assessed circadian phase and/
or period using specific study procedures. Specifically, timing of the CBTmin and the dim light melatonin onset 
(DLMO) were used as circadian phase markers collected during constant routine or constant posture conditions 
(see45 and46 for detailed description). Intrinsic circadian period of CBT and of melatonin were assessed using 
forced desynchrony protocols29,41,47,48 as previously described29,30. Forced desynchrony protocols involved the 
collection of continuous CBT measurement and/or hourly blood sampling during a minimum of two weeks 
while participants maintained a sleep/wake cycle that was substantially greater than 24 hours (e.g., T = 28 or 
T = 42.85 hours). This allowed for the assessment of circadian measures under a T cycle to which the circadian 
system cannot entrain while light intensity was maintained at 0 lux during scheduled sleep and <15 lux during 
scheduled wakefulness. Additionally, circadian phase angle for CBT (difference between timing of CBTmin and 
wake time averaged from the week prior to admission) and melatonin (difference between DLMO and wake time) 
were determined.
Genotypes. UKBiobank study: Genotyping was performed by the UK Biobank, and genotyping, quality con-
trol, and imputation procedures have been described49. In brief, blood was collected from participants, and DNA 
was extracted from the buffy coat samples. Participant DNA was genotyped on two arrays, UK BiLEVE and UKB 
Axiom with >95% common content and genotypes for ~800,000 SNPs were imputed to the Haplotype Reference 
Consortium reference panel50. We examined association of directly genotyped SNP rs35333999 and genotyped 
and well-imputed common variants (minor allele frequency >0.001 and imputation quality score >0.3) within a 
400 kb region to capture multiple independent association signals.
In-laboratory Study: DNA was extracted from venous blood samples collected from each in-laboratory 
study participant. The PER2 SNP rs35333999 was genotyped using the Sequenom platform that distinguishes 
allele-specific primer extension products by mass spectrometry (MALDI-TOF; Broad Institute, Cambridge, 
Massachusetts)51. Quality control and Hardy Weinberg Equilibrium were assessed using the genetic software 
PLINK52. An additional 58 African-American and Hispanic ancestry informative markers were genotyped using 
the same platform to identify the subset of subjects with genetic European ancestry and to correct for population 
stratification53,54.
Association analysis. Association testing in both cohorts employed an additive genetic model of PER2 
rs35333999 T with self-reported chronotype or circadian measures using linear or logistic regression analysis in 
PLINK and adjustment for covariates: age, sex, and five principal components of ancestry. In the UK Biobank, 
single SNP association analysis to chronotype was performed for SNPs in a 400 kb region encompassing the 
PER2 gene and included genotyping array as an additional covariate. Conditional genetic association analysis 
included further adjustment for SNPs (rs35333999 or regional lead SNP rs80271258) in regression models. 
P-values < 5 × 10−8 were considered significant. Analyses of in-laboratory participants of European ancestry 
(n = 196) as well as for the entire multiethnic sample (n = 252) were performed. In the multi-ethnic sample, 
an additional race/ethnicity covariate was included. P-values < 0.05 were considered significant for associations 
between PER2 rs35333999 and circadian phenotypes. Sensitivity analysis was performed using the Welch’s t-test 
for unequal variances55 testing T allele carriers (TC and TT) vs CC homozygotes on covariate-adjusted residuals 
(age, sex, and 5 principal components of ancestry) for both melatonin and core-body temperature period. The 
additive effect of the TT genotype was not considered in this sensitivity analysis.
Data Availability
The data that support the findings of this study from the UK BioBank will be made available at https://sleepge-
netics.org and the underlying genotype and phenotype data are available through application to the UK Biobank. 
Other phenotype data are available on request, due to privacy or other restrictions, through co-corresponding 
author Dr. Scheer (fscheer@bwh.harvard.edu).
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